Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program
Objective response rates, disease control rates, and a PFS comparable to that in the phase 2 FIGHT-202 trial was reported with pemigatinib use in this Canadian PSP cohort.
Authors
- Winson Y. Cheung (ORCID: https://orcid.org/0000-0002-3679-4290)
- Ravi Ramjeesingh (ORCID: https://orcid.org/0000-0001-5584-3505)
- Brandon S. Sheffield (ORCID: https://orcid.org/0000-0002-9234-6134)
- Jamil Asselah (ORCID: https://orcid.org/0000-0002-6875-6512)
- Jennifer J. Knox (ORCID: https://orcid.org/0000-0003-3474-6647)
- Philip Q. Ding (ORCID: https://orcid.org/0000-0002-0413-5485)
- Vincent C. Tam (ORCID: https://orcid.org/0000-0001-8732-0530)
- Tanecia Mitchell (ORCID: https://orcid.org/0000-0002-4032-913X)
- Anne-Julie Gaudreau
Institutions
- Dalhousie University (CA)
- University of Alberta (CA)
- University of Calgary (CA)
- Royal Victoria Regional Health Centre (CA)
- McGill University Health Centre (CA)
- Princess Margaret Cancer Centre (CA)
- Royal Victoria Hospital (CA)
- Thermal-Lube (Canada) (CA)
- William Osler Health System (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.3390/curroncol32070405
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Incyte